Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
ApexOnco Front Page
Recent articles
The first data are dribbled out, but cross-trial comparisons look uninspiring.
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
But will the FDA accept the surrogate endpoint used in ASC4First?
This weekend’s oncology conference will feature at least 30 different ADC projects.
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.